PDS Biotechnology Corp. Announces Clinical Collaboration with Merck to Evaluate Combination of Versamune® PDS0101 and KEYTRUDA® (pembrolizumab) for Metastatic Head and Neck Cancer
- Category: Antibodies
- Published on Monday, 10 July 2017 20:44
- Hits: 1052
NORTH BRUNSWICK, NJ, USA I July 10, 2017 I PDS Biotechnology Corporation ("PDS"), a private clinical stage immuno-oncology company developing novel immunotherapies, has entered a clinical trial collaboration agreement with a subsidiary of Merck (known as MSD outside the United States and Canada) to evaluate the combination of PDS's lead Versamune®-based immunotherapy, PDS0101, with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in a Phase II clinical trial. The planned clinical trial will evaluate the safety and efficacy of the combination in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HPV16) infection after failure with platinum-based chemotherapy.
"We are honored to collaborate with Merck – one of the world's leading cancer immuno-oncology companies – on this innovative, investigational combination cancer treatment for head and neck cancer patients," said Dr. Frank Bedu-Addo, CEO of PDS. "This collaboration is supported by our recent Phase IIa human clinical data demonstrating that PDS0101 uniquely combined induction of high levels of active tumor-targeting T-cells with an excellent safety profile. If PDS0101's strong human immunological responses and superior safety profile are confirmed by demonstration of clinical benefit for HPV-cancer patients in multiple upcoming Phase IIb trials, including this important alliance with Merck in combination with a checkpoint inhibitor, PDS will be uniquely positioned to meaningfully impact clinical outcomes across a wide range of patients with HPV-related cancers."
Details of the collaboration were not disclosed.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Versamune® is a registered trademark of PDS Biotechnology Corporation, North Brunswick, NJ, USA.
About the Versamune® T-Cell Activating Platform:
About PDS Biotechnology Corporation:
SOURCE: PDS Biotechnology